Rapid and Self-Administrable Capillary Blood Microsampling Demonstrates Statistical Equivalence with Standard Venous Collections in NMR-Based Lipoprotein Analysis

Abstract

We investigated plasma and serum blood derivatives from capillary blood microsamples (500 μL, MiniCollect tubes) and corresponding venous blood (10 mL vacutainers). Samples from 20 healthy participants were analyzed by 1 H NMR, and 112 lipoprotein subfraction parameters; 3 supramolecular phospholipid composite (SPC) parameters from SPC 1 , SPC 2 , and SPC 3 subfractions; 2 N-acetyl signals from α-1-acid glycoprotein (Glyc), GlycA, and GlycB; and 3 calculated parameters, SPC (total), SPC 3 /SPC 2 , and Glyc (total) were assessed. Using linear regression between capillary and venous collection sites, we explained that agreement (Adj. R 2 ≥ 0.8, p < 0.001) was witnessed for 86% of plasma parameters (103/120) and 88% of serum parameters (106/120), indicating that capillary lipoprotein, SPC, and Glyc concentrations follow changes in venous concentrations. These results indicate that capillary blood microsamples are suitable for sampling in remote areas and for high-frequency longitudinal sampling of the majority of lipoproteins, SPCs, and Glycs.

Cross-Validation of Metabolic Phenotypes in SARS-CoV-2 Infected Subpopulations Using Targeted Liquid Chromatography–Mass Spectrometry (LC-MS)

“…However, we provide evidence that using such an approach can provide value in the biological validation of phenotypes where matched biofluids are not available, indicating that biofluids independently collected using nonmatched protocols (plasma vs serum) may still serve as a valuable validation set to corroborate phenotypic trends and signatures. This builds upon our previous work where we have demonstrated that targeted phenotyping workflows can be robust to different sampling conditions, including blood collection type and degrees of hemolysis when using targeted lipidomic and lipoprotein phenotyping . These findings justify that there remains value in validating biomarker signatures in cohorts in which samples may have been collected or treated differently, withstanding that the methodology is robust to external influences.…”

“…This builds upon our previous work where we have demonstrated that targeted phenotyping workflows can be robust to different sampling conditions, including blood collection type and degrees of hemolysis when using targeted lipidomic 70 and lipoprotein phenotyping. 71 These findings justify that there remains value in validating biomarker signatures in cohorts in which samples may have been collected or treated differently, withstanding that the methodology is robust to external influences.…”